Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
Previous Symbol
CUSIPN/A
Phone510-474-0170
Debt
Debt-to-Equity RatioN/A
Current Ratio6.12
Quick Ratio6.12
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$20.06 million
Price / Sales8.31
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.89 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)($2.09)
Net Income$-36,950,000.00
Net Margins-70.54%
Return on Equity-24.08%
Return on Assets-18.76%
Miscellaneous
Employees55
Outstanding Shares24,190,000
Market Cap$166.64 million
OptionableNot Optionable
Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions
What is Protagonist Therapeutics' stock symbol?
Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."
How were Protagonist Therapeutics' earnings last quarter?
Protagonist Therapeutics Inc (NASDAQ:PTGX) posted its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.01. The business had revenue of $6.12 million for the quarter, compared to analyst estimates of $6.35 million. Protagonist Therapeutics had a negative return on equity of 24.08% and a negative net margin of 70.54%. View Protagonist Therapeutics' Earnings History.
When is Protagonist Therapeutics' next earnings date?
What price target have analysts set for PTGX?
5 analysts have issued 12 month target prices for Protagonist Therapeutics' stock. Their predictions range from $13.00 to $32.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $19.40 in the next year. This suggests a possible upside of 181.6% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.
What is the consensus analysts' recommendation for Protagonist Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.
Has Protagonist Therapeutics been receiving favorable news coverage?
News coverage about PTGX stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Protagonist Therapeutics' key competitors?
Some companies that are related to Protagonist Therapeutics include Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Rocket Pharmaceuticals (RCKT), Eagle Pharmaceuticals (EGRX), Omeros (OMER), Viking Therapeutics (VKTX), Inflarx (IFRX), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Eidos Therapeutics (EIDX), Karyopharm Therapeutics (KPTI), AMAG Pharmaceuticals (AMAG) and MacroGenics (MGNX).
Who are Protagonist Therapeutics' key executives?
Protagonist Therapeutics' management team includes the folowing people:
- Dr. Dinesh V. Patel, CEO, Pres, Sec. & Director (Age 61)
- Dr. Richard S. Shames, Chief Medical Officer (Age 58)
- Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 68)
- Mr. Thomas P. O'Neil, Chief Financial Officer (Age 53)
- Dr. Mark Smythe, VP of Technology & Alliances (Age 53)
When did Protagonist Therapeutics IPO?
(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.
Who are Protagonist Therapeutics' major shareholders?
Protagonist Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.35%), Renaissance Technologies LLC (2.22%), Vanguard Group Inc. (2.19%), Vanguard Group Inc (2.19%), Dimensional Fund Advisors LP (1.52%) and Jennison Associates LLC (1.45%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.
Which major investors are selling Protagonist Therapeutics stock?
PTGX stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Citadel Advisors LLC, BlackRock Inc. and Algert Global LLC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Insider Buying and Selling for Protagonist Therapeutics.
Which major investors are buying Protagonist Therapeutics stock?
PTGX stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Wedge Capital Management L L P NC, JPMorgan Chase & Co., JPMorgan Chase & Co., Dimensional Fund Advisors LP, Laurion Capital Management LP and Renaissance Technologies LLC. View Insider Buying and Selling for Protagonist Therapeutics.
How do I buy shares of Protagonist Therapeutics?
Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protagonist Therapeutics' stock price today?
One share of PTGX stock can currently be purchased for approximately $6.89.
How big of a company is Protagonist Therapeutics?
Protagonist Therapeutics has a market capitalization of $166.64 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe.
What is Protagonist Therapeutics' official website?
How can I contact Protagonist Therapeutics?
Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]
MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
